Valeritas Holdings, Inc.

Equities

VLRXQ

US91914N3017

Medical Equipment, Supplies & Distribution

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-4.76%	-96.52%

2020	Valeritas Holdings, Inc. Went Out of Business	CI
2020	First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	CI

Valeritas Holdings, Inc. Provides Revenue Guidance for the Full Year and Fourth Quarter Ended December 31, 2017

January 08, 2018 at 06:00 pm IST

Valeritas Holdings, Inc. provided revenue guidance for the full year and fourth quarter ended December 31, 2017. For the full year, the company expects revenue to reach $20 million, in line with prior guidance. Fourth quarter revenue is expected to be approximately $5.6 million, which would represent growth of 16% year-over-year and 10% sequentially.

Latest news about Valeritas Holdings, Inc.

Valeritas Holdings, Inc. Went Out of Business	30/20/30	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Approved for Valeritas Holdings, Inc.	08/20/08	CI
First Motion for Exclusivity Period Extension Approved For Valeritas Holdings, Inc.	03/20/03	CI
First Motion for Exclusivity Period Extension Filed by Valeritas Holdings, Inc.	21/20/21	CI
Combined Disclosure Statement and Liquidation Plan Approved for Solicitation Purpose on Interim Basis for Valeritas Holdings, Inc.	21/20/21	CI
First Amended Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	15/20/15	CI
Combined Joint Liquidation Plan & Disclosure Statement Filed by Valeritas Holdings, Inc.	06/20/06	CI
Valeritas Holdings, Inc. Announces Management Changes	03/20/03	CI
Zealand Pharma A/S completed the acquisition of substantially all assets of Valeritas Holdings, Inc.	02/20/02	CI
Motion for Asset Sale Approved for Valeritas Holdings, Inc.	20/20/20	CI
Final DIP Financing Approved for Valeritas Holdings, Inc.	13/20/13	CI
Notice for Auction Cancellation Filed by Valeritas Holdings, Inc.	13/20/13	CI
Bidding Procedure Approved for Valeritas Holdings, Inc.	06/20/06	CI
Valeritas Holdings, Inc. Terminates Joseph Saldanha as Chief Business Officer, Effective from March 6, 2020	29/20/29	CI
Valeritas Holdings, Inc.(OTCPK:VLRX.Q) dropped from NASDAQ Composite Index	19/20/19	CI
The United States Bankruptcy Court for the District of Delaware Enters an Order Granting an Interim Approval to Valeritas Holdings, Inc.'s Proposed Senior Secured Priming Debtor-In-Possession Financing Facility	15/20/15	CI
Interim DIP Financing Approved for Valeritas Holdings, Inc.	14/20/14	CI
Asset Purchase Agreement Filed by Valeritas Holdings, Inc.	14/20/14	CI
Valeritas Holdings, Inc.(NasdaqCM:VLRX) dropped from S&P TMI Index	12/20/12	CI
Motion for Joint Administration Approved for Valeritas Holdings, Inc.	12/20/12	CI
Motion for Asset Sale Filed by Valeritas Holdings, Inc.	10/20/10	CI
Valeritas Holdings, Inc. Filed for Bankruptcy	09/20/09	CI
Motion for Joint Administration Filed by Valeritas Holdings, Inc.	09/20/09	CI
Zealand Pharma A/S entered into a stalking horse agreement to acquire substantially all assets of Valeritas Holdings, Inc.	09/20/09	CI
Valeritas Holdings, Inc. Announces Appointment of Melanie Hansen as Treasurer and Principal Accounting Officer, Effective January 13, 2020	11/20/11	CI

Chart Valeritas Holdings, Inc.

Duration

Period

More charts

Company Profile

Valeritas Holdings, Inc. is a United States-based medical technology company. The Company's product, V-Go Wearable Insulin Delivery device (V-Go), is a wearable, basal-bolus insulin delivery device for adult patients requiring insulin that enables patients to administer a continuous preset basal rate of insulin over 24 hours. V-Go is a small wearable and completely disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body's normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. It has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
VALERITAS HOLDINGS, INC.	-96.52%	167K
ABBOTT LABORATORIES	-7.05%	175B
MEDTRONIC PLC	-1.98%	107B
BECTON, DICKINSON AND COMPANY	-7.40%	65.05B
DEXCOM, INC.	+0.85%	50.76B
CENCORA, INC.	+7.34%	43.14B
HOYA CORPORATION	+5.93%	41.46B
METTLER-TOLEDO INTERNATIONAL, INC.	+14.71%	30.69B
TERUMO CORPORATION	+13.37%	25.39B
ZIMMER BIOMET HOLDINGS, INC.	-5.55%	23.69B

Other Medical Equipment, Supplies & Distribution